Fructo-oligosaccharides and glucose homeostasis: a systematic review and meta-analysis in animal models
Cindy Le Bourgot, Emmanuelle Apper, Sophie Blat, Frédérique Respondek

To cite this version:
Cindy Le Bourgot, Emmanuelle Apper, Sophie Blat, Frédérique Respondek. Fructo-oligosaccharides and glucose homeostasis: a systematic review and meta-analysis in animal models. Nutrition and Metabolism, BioMed Central, 2018, 15, pp.9. <10.1186/s12986-018-0245-3>. <hal-01709937>

HAL Id: hal-01709937
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01709937
Submitted on 15 Feb 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Fructo-oligosaccharides and glucose homeostasis: a systematic review and meta-analysis in animal models

Cindy Le Bourgot 1, Emmanuelle Apper 1, Sophie Blat 2 and Frédérique Respondek 1*

Abstract

The aim of this systematic review was to assess the effect of fructo-oligosaccharide supplementation on glucose homeostasis. The search process was based on the selection of publications listed in the Pubmed-Medline database until April 2016 to identify studies evaluating the impact of short-chain fructo-oligosaccharides or oligofructose on glucose homeostasis. Twenty-nine trials were included in the systematic review and the meta-analysis was performed on twelve of these papers according to the inclusion criteria. Fasting blood concentrations of glucose and insulin were selected as pertinent criteria of glucose homeostasis for the meta-analysis. The consumption of fructo-oligosaccharides decreased fasting blood glycaemia levels, whatever the metabolic status (healthy, obese or diabetic) and diet (low-fat or high-fat) throughout the experiment. This reduction was linear with prebiotic dose (from 0 to 13% of the feed). Fasting insulinaemia also decreased linearly with fructo-oligosaccharide supplementation but the reduction was only significant in rodents fed a low-fat diet. Potential underlying mechanisms include gut bacterial fermentation of fructo-oligosaccharides to short-chain fatty acids (SCFA) and bacterial modulation of bile acids, both interacting with host metabolism.

This systemic review, followed by the meta-analysis, provides evidence that fructo-oligosaccharide supplementation has a significant effect on glucose homeostasis whatever the health status and diet consumed by animals.

Keywords: Fructo-oligosaccharides, Prebiotic, Dietary fibres, Glycaemia, Insulinaemia

Background

Over the past decades, a food transition has taken place, characterized by the consumption of high energy density food. These dynamic changes in dietary macronutrient ingestion and lifestyle (increase in sedentarity) are leading causes of the growing prevalence of metabolic disorders such as obesity and type 2 diabetes. Emerging evidence suggests that bacterial dysbiosis within the gut may be one of the mechanisms of the pathogenesis of these metabolic diseases. Epidemiological and clinical studies have demonstrated that intake of dietary fibres, known for their promotion of more diverse/balanced intestinal microbiota, is inversely related to obesity [1] and type 2 diabetes [2]. Thus, the use of dietary fibre supplements to restore an optimal balance of intestinal microbiota may positively affect host metabolism, representing a potential beneficial strategy for individuals with metabolic disorders.

Dietary fibres are edible carbohydrate polymers, which are neither digested nor absorbed in the human small intestine [3], and have demonstrated beneficial physiological effect. There are different types of fibres, and according to their nature (naturally occurring in food, obtained from food raw material, or synthesized), physical properties, and fermentability in the gut, they do not have the same benefits for the consumer [4].

Most of the beneficial effects associated with high-fibre diets are linked to their low caloric value (2 kcal/g vs 4 kcal/g for other carbohydrates), their low postprandial glucose excursion (possibly due to their viscosity) [5] or their high content in mandatory micronutrients. Their fermentation by the gastrointestinal microbiota is also a cue of their beneficial effect on metabolism, especially due to their impact on glucose homeostasis [6]. Indeed, short-chain fatty acids (SCFA) produced by bacterial
GLP-1 binds to its specific receptor on pancreatic β-cells, stimulating insulin secretion, which participates in the regulation of glucose metabolism [8]. The continuous communication between the gut and the pancreas, that is mandatory to maintain glucose homeostasis, is named the enteroh-insular axis.

Several studies have indeed pointed out differences in the composition of the faecal microbiota of healthy people and patients with metabolic disorders, as recently reviewed [9].

β-fructans, composed of a terminal glucose molecule linked to fructose molecules by a β1–2 bound with varying degrees of polymerisation, are an example of such fermentable, non-viscous dietary fibres. Short-chain molecules of fructo-oligosaccharides (scFOS) and oligofructose (OF) are called fructo-oligosaccharides (FOS), while longer molecules are called inulin. Both are naturally present in various fruits and vegetables (including chicory), or can be produced from beet sugar. They are frequently used to replace sugars in the formulation of low-sugar foods in order to lower the postprandial glycaemic response [10, 11], to reduce energy content, or to enrich foods with dietary fibres. They are selectively fermented by a limited number of bacteria, especially Bifidobacteria, in the large intestine. Their health benefits for gut physiology in humans have been known for several years, but some recent studies point out that they may also have systemic benefits [12]. Yet, the capacity of FOS to lower fasting serum glucose in humans remains unclear [13], and further analysis of available animal studies would help to better understand the mechanism of action of FOS on glucose homeostasis and the relevance for human subpopulations that may benefit from these fibre supplementations.

This systematic review therefore focuses on the effects of scFOS and OF on glucose metabolism in animal models. A meta-analysis was then focused on the effect of dietary supplementation of these prebiotic fibres on fasting blood glycaemia and insulinemia in rodents. We only included rodents in the meta-analysis due to the greater number of studies carried out on this animal model, and the larger number of animals used in each study compared to other animal species.

**Material and methods**

**Systematic review**

For this review we defined short-chain fructo-oligosaccharides (scFOS) as molecules produced from beet sugar and having a degree of polymerization (DP) between 3 and 5, and oligofructose (OF) as molecules obtained from hydrolysis of inulin and having a DP between 2 and 8. All original research published in English and listed on PubMed-Medline until April 2016 using the following keywords: fructo(−)oligosaccharide(s), oligofructose and with one of the following words: blood glucose, glyc(a)emia, insulin, insulin(a)emia, diabetes, antidiabetic, metabolic syndrome were selected. The filter: “Other Animals” was applied. Seventy-nine articles were retrieved on this basis and they were selected for the review if they matched the described inclusion criteria (Fig. 1). Twenty-four articles were finally included from this search and 5 articles were manually added based on the same inclusion criteria.

**Meta-analysis**

The aim of the meta-analysis was to focus on the effects of dietary supplementation with FOS (scFOS or OF) on fasting blood glycaemia and insulinemia, indicative of metabolic health, in the studies in rodents retrieved from the systematic review. Selected papers for the meta-analysis therefore contained, at least, data on the physiological status of rodents (i.e. healthy, diabetic or obese), on diet characteristics and on blood parameters. Selected papers presenting more than one experiment were separated into experiments that were individually encoded.

Each comparison between control and prebiotic (scFOS or OF) was also individually encoded within each experiment containing more than 2 treatments. A total of 12 papers and 13 experiments were pooled in the database [14–25].

**Statistical analysis**

The interpretation of this database was based on a statistical meta-analysis [26, 27]. The basic statistical model applied to the data was [26]:

\[
Y_{ijk} = \mu + PRE_i + EXP_j + E_{ijk},
\]

where \(Y_{ijk}\) = basal glycaemia (or insulinemia); \(PRE_i\) = fixed effect of prebiotic; \(EXP_j\) = fixed effect of experiment \(j\), and \(E_{ijk}\) = random residual error.

Prebiotic effect was first tested qualitatively (control vs FOS) and then as a covariable according to the dose of FOS supplementation expressed as % in diet. Normalized residuals greater than 3 were discarded from the analysis. The parameters of interest were the least square means (control vs FOS) or the adjusted equation (covariance analysis), the \(P\)-value for the FOS effect, and the outlier treatment that presented normalized residuals > 2. The fixed effect of experiment was always highly significant (\(P < 0.001\)) and is thus never provided. An effect was considered significant at \(P < 0.05\).
Results

Glucose homeostasis

Systematic review

Database We retrieved 29 studies evaluating the effects of a dietary supplementation with scFOS or OF on glucose homeostasis. Most of these studies was conducted in rodents (6 and 18 experiments in mice and rats respectively). The last 5 studies were performed in other animal species, namely veal calves \((n = 1)\), horses \((n = 1)\), dogs \((n = 2)\) and cats \((n = 1)\). The metabolic status of the animals was different between the experiments with either healthy, genetically obese or diet-induced obese (DIO), or genetically predisposed or streptozotocin-induced diabetic individuals. In addition, the type of diet used in the selected experiments varied regarding the energy provided by fat, and we characterized it as "low-fat" when fat provided less than 20% of the diet's energy (standard diet), and as "high-fat" when fat provided more than 20% of the diet's energy (high-fat diet), generally at the expense of carbohydrates. A synthetic description of the selected studies conducted in healthy rodents, or in obese or diabetic rodents, is presented in Tables 1 and 2 respectively. Papers on other species are described in Table 3.

Glucose homeostasis parameters In studies conducted in healthy rodents fed with standard diets, FOS supplementation generally did not affect blood fasting glucose concentration. Although fasting glycaemia was not changed, fasting blood insulin was lowered in 4 out of the 6 studies where it was measured. FOS supplementation reduced postprandial blood glucose level in half of the studies, in association with decreased insulin concentration when measured. When rodents were fed a high-fat diet (more than 60% of energy provided by fat), supplementation with FOS significantly increased fasting insulinaemia and decreased in parallel fasting glycaemia, and the same results were obtained in the fed state (Table 1). In rodents with obesity or type 2 diabetes, the same tendency towards reduction of glycaemia was observed with FOS supplementation, particularly in postprandial condition. Effects on insulinaemia were more controversial, with either a reduction in obese rats or an increase in diabetic rat models (Table 2).

In addition, five studies on animal models other than rodents (i.e. veal calves, Arabian horses, Beagle dogs, neutered short-hair cats) were retrieved from the literature search (Table 3). Contrary to studies involving rodents, most of these studies were conducted in a crossover design and no study was performed with a high-fat diet for the considered species, even though the percentage of energy provided by fat in the diet of dogs and cats was around 30%, considered as high for rodents but normal for pets. In these studies, scFOS supplementation had no effect on fasting blood glucose and insulin, except for the study with obese horses in which it reduced fasting blood insulin [28]. In these species, the effects of scFOS on glucose homeostasis were more visible in postprandial state or in a dynamic model of glucose tolerance test. In veal calves, scFOS supplementation decreased the postprandial glucose response to a lactose-rich meal and increased postprandial insulin secretion [29]. Two recent studies on obese and insulin resistant horses [28] and dogs [30], showed that a 6-week dietary
### Table 1 Effects of scFOS/OF supplementation on glucose homeostasis in healthy rodents

| Animal model | Diet | FOS dose | Duration | Fasting condition | Postprandial condition | Other metabolic results | Microbiota analysis (yes/no) | Included in meta-analysis (yes/no) | References |
|--------------|------|----------|----------|-------------------|------------------------|------------------------|-----------------------------|---------------------------------|------------|
| Male Wistar rats | 7% E fat, 73% E CHO | 10% OF | 4 w | ND | ND | Fed | ↓ | ↓ | TG, PP (blood and liver) = tot. Chol (blood and liver) | NO | YES | [40] |
| Male Wistar rats | 7% E fat, 73% E CHO | 10% OF | 4 w | = | ↓ | Fed (after 30d) OGGT (after 18d) | ↓ (cardiac blood) = ↓ (cardiac blood) | NO | NO | [41] |
| Male Sprague-Dawley rats | 9.8% E fat, 77.5% E CHO | 5% scFOS | 3–5 w | = | ↓ after 5 w | ND | ND | NO | YES | [25] |
| Male Sprague-Dawley rats | 9.8% E fat, 77.5% E CHO | 5% OF 10% OF | 10 w | = | ↓ | ND | ND | NO | YES | [21] |
| Male Wistar/ST rats | 9.8% E fat, 77.5% E CHO | 5% scFOS | 48 d | = | = | OGGT | = | = | NO | YES | [23] |
| Male Sprague-Dawley rats | 11.8% E fat, 69.4% E CHO (starch or fructose) | 10% OF | 4 w | ND | ND | Fed | = | = | ↓ TG | leptin with fructose diet only | YES | YES | [61] |
| Female C57BL/6 J mice ± n-3 PUFA | 14.3% E fat, 589% E CHO | 0.2 g OF/ d | 24 d | ↓ (in n-3 depleted mice only) | = | OGGT | = | = | NO | YES | [22] |
| Male Sprague-Dawley rats | 16.4% E fat, 65.1% E CHO | 2.5% or 5% scFOS | 7 w | = (tail and portal blood) | = (tail blood) ↓ (portal blood) with 5% scFOS | IPGTT ↓ (2.5% at 30 min) | ND | = | NO | NO | [58] |
| Male Wistar rats | 23.9% E fat, 568% E CHO | 5% OF | 3 w | ND | ND | Fed | = | = | NO | NO | [83] |
| Male Sprague-Dawley rats | 27.5% E fat, 53.5% E CHO | 10% scFOS | 3 w | ND | ND | Fed | ↓ | = | plasma acetate, propionate, butyrate | NO | YES | [38] |

**Standard diet:** less than 20% of energy provided by fat.

**High-fat diet:** 20 to 60% of energy provided by fat.

**Fasting condition:** ND = not determined.

**Postprandial condition:** Fed, OGTT, IPGTT = OGTT (after 18d), IPGTT (after 30 min).

**Microbiota analysis:** YES = yes, NO = no.

**Included in meta-analysis:** YES = yes, NO = no.
| Animal model                      | Diet                                      | FOS dose | Duration | Fasting condition | Postprandial condition | Other metabolic results                                                                                                                                                                                                 |
|-----------------------------------|-------------------------------------------|----------|----------|-------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Male C57BL/6 J gnotobiotic mice   | 34.9% E fat, 26.3% E CHO                 | 10% scFOS| 6 w      | ND                | ND                     | Fed (5 h after meal) = = AUCg = I (20 and 60 min) ↓↑ leptin YES NO [46]                                                                                                                                                                |
| Male C57BL/6 J mice               | Exp 2 HF2: 58% E fat, 26% E CHO           | 10% OF   | 4–8 w    | =                 | =                      | ND ND ND ↓↑ colon proglucagon mRNA NO YES [16]                                                                                                                                                                                 |
| Male C57BL/6 J mice               | 72% E fat, < 1% E CHO                    | 10% OF   | 4 w      | ↓↑                | ↑                      | Fed IPGTT ↓ AUCg ↑ pancreatic insulin glucose infusion rate and ↓ hepatic glucose production (clamp euglycaemic hyperinsulinaemic) ↑ colon proglucagon mRNA ↑ GLP-1 (plasma and colon) NO YES [15] |
| Male C57BL/6 J mice               | Exp 1 HF1: 72% E fat, < 1% E CHO          | 10% OF   | 4–8 w    | ↓↑                | ↑                      | ND ND ND ↑ colon proglucagon mRNA NO YES [16]                                                                                                                                                                                 |

CHO carbohydrates, Chol cholesterol, d days, E energy, FFA free fatty acids, FOS fructo-oligosaccharides, G glucose, I insulin, MCP-1 monocyte chemoattractant protein-1, ND no data, OF oligofructose, PAI-1 plasminogen activator inhibitor-1, PP phospholipids, PUFA polyunsaturated fatty acids, RBC red blood cells, scFOS short-chain fructooligosaccharides, TG triglycerides, w weeks

*Fed condition not clearly indicated in the study
Table 2 Effects of scFOS/OF supplementation on glucose homeostasis in obese or diabetic rodents

| Animal model                  | Diet                                           | FOS dose | Duration | Fasting condition | Postprandial condition | Other metabolic results                                                                 | Microbiota analysis (yes/no) | Included in meta-analysis (yes/no) | References |
|------------------------------|------------------------------------------------|----------|----------|-------------------|------------------------|------------------------------------------------------------------------------------------|-------------------------------|-----------------------------------|------------|
| Male Obese Zucker rats       | Standard diet: less than 20% of energy provided by fat | 7% E fat, 73% E CHO | 10 w     | Fed (tail vein)   | −                      | = = = = PP, TG and Chol (cava and portal veins) = hepatic TG and PP                      | NO                            | YES                               | [39]       |
| Female Obese Zucker rats     | 9.8% E fat, 77.5% E CHO                          | 5% scFOS | 100 d    | −                 | ND                     | = = THG and Chol = HbA1C                                                                 | NO                            | YES                               | [20]       |
| Male Sprague-Dawley rats, DIO| 9.8% E fat, 77.5% E CHO                          | 3% OF    | 6 w      | OGTT              | =                      | ↑ PYY OGTT and AUC PYY = GLP-I = liver TG                                                | YES                           | YES                               | [17]       |
| Male Sprague-Dawley rats, DIO| 9.8% E fat, 77.5% E CHO                          | 10% OF   | 8 w      | OGTT              | ↓ 90 min              | ↓ leptin OGTT (AUC leptin) ↑ fasting PYY and AUC PYY ↑ fasting portal GLP-1             | YES                           | YES                               | [14]       |
| Diabetes-prone BB rats       | 16.4% E fat, 65.1% E CHO                         | 5% OF    | 160 d    | −                 | ND                     | = = TG and Chol = HbA1C                                                                 | NO                            | NO                                | [84]       |
| Male Wistar rats, Streptozotocin | 7% E fat, 73% E CHO                          | 10% OF   | 6 w      | −                 | ND                     | ↑ pancreatic insulin and % beta cells (= beta cell mass) ↓ portal and colon GLP-1 ↑ colon proglucagon and PC1 mRNA (= in ileum) | NO                            | YES                               | [37]       |
| Male Wistar rats, PX - 407   | 9.8% E fat, 77.5% E CHO                          | 10% or 15% scFOS | 6 w     | −                 | ND                     | ↑ caecal GLP-1                                                                         | YES                           | NO                                | [56]       |
| Male Sprague-Dawley rats, DIO| High-fat diet: 20 to 60% of energy provided by fat | g/100 g: casein (20%), sucrose (49.5), soybean oil (100%), lard (10.0) | 10% OF | −                 | OGTT                  | ↓ leptin, ghrelin, GIP OGTT ↓ GLP-1 OGTT ↓ plasma DDP4                                  | YES                           | YES                               | [24]       |
| Male Wistar rats, Streptozotocin | 20.4% E fat, 59.9% E CHO                          | 10% scFOS | 2–6 w    | − (after 2, 4 and 6 w) | ND                     | ↓ urinary glucose excretion (after 4, 5 and 6 w) ↓ plasma cholesterol, creatinine and urea | YES                           | YES                               | [19]       |
| Ob/ob C57BL/6 mice           | High-fat diet: more than 60% of energy provided by fat | 60% E fat, 20% E CHO | 10% OF | −                 | OGTT                  | ↓ plasma TG, LPS ↑ plasma GLP-1 and colon proglucagon mRNA ↑ colon L-cells number       | YES                           | YES                               | [18]       |

AUC area under the curve, CHO carbohydrates, Chol cholesterol, d days, DIO diet-induced obesity, DPP4 dipeptidyl peptidase-4, E energy, FOS fructo-oligosaccharides, G glucose, I insulin, LPS lipopolysaccharide, ND no data, OF oligofructose, PP phospholipids, scFOS short-chain fructooligosaccharides, TG triglycerides, w weeks

* Fed condition not clearly indicated in the study
| Animal model                      | Diet                          | FOS dose          | Duration | Fasting condition | Postprandial condition | Other metabolic results                                                                 | Microbiota analysis (yes/no) | Included in meta-analysis (yes/no) | References |
|----------------------------------|-------------------------------|-------------------|----------|-------------------|------------------------|------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------|------------|
| Healthy male veal calves         | Whole milk + milk replacer    | 10 g scFOS/d      | 3 w      | =                 | =                      | Lactose feeding ↓ (after 2 h to 5 h) ↑ (after 2 h) ↓ lactate after lactose feeding (after 3 h and 4 h) = TG (blood) | NO                          | NO                                | [29]       |
| Obese male Arabian horses        | Concentrate feeds and hay     | 45 g scFOS/d      | 6 w      | =                 | ↓                      | FSIGTT = Sg ↓ ARI ↑ SI = TG and leptin (fasting blood)                                    | NO                          | NO                                | [28]       |
| Obese male Beagle dogs           | 32% E fat, 44% E CHO          | 1% scFOS          | 6 w      | =                 | =                      | Euglycemic hyperinsulinaemic clamp ↑ glucose infusion ↑ insulin sensitivity ↓ HOMA-IR = TG and Chol (blood) | NO                          | NO                                | [30]       |
| Obese male Beagle dogs on weight-loss program | 95% E fat, 56% E CHO | 3% scFOS Vs 1% scFOS | 6 w      | = =               | ND ND ND ND ND haptoglobin | NO                          | NO                                | [31]       |
| Normal or obese short-hair neutered cats | 38% E fat, 8% E CHO | 25% mix OF/insulin | 4 w      | =                 | IVGTT = =             | = Chol, NEFA, leptin                                                                   | NO                          | NO                                | [32]       |

CHO carbohydrates, Chol cholesterol, d days, E energy, FOS fructo-oligosaccharides, G glucose, I insulin, ND no data, OF oligofructose, scFOS short-chain fructooligosaccharides, TG triglycerides, w weeks

*Fed condition not clearly indicated in the study
supplementation with scFOS could improve insulin sensitivity with no change in body weight. In horses, the frequently sampled intravenous glucose tolerance test (FSIGTT) highlighted that this improvement in insulin sensitivity was accompanied by a reduction in acute insulin response to glucose, with no change in glucose effectiveness. When obese dogs were submitted to a weight loss program with an energy-restricted diet, no effect of scFOS supplementation was observed on fasting blood glucose or insulin [31]. In normal weight and obese cats, the diet supplementation with a mixture of OF and inulin did not affect glucose homeostasis in fasting condition and after an IV glucose bolus [32].

**Meta-analysis**
The meta-analysis was performed on 12 papers and 13 experiments. It represented 32 treatments for the fasting glycaemia parameter, and 14 treatments for fasting insulinaemia (Table 4).

**Qualitative analysis: control vs FOS**
FOS supplementation significantly decreased fasting blood glycaemia, whatever the metabolic status of the rodents and the diet administered throughout the experiment ($P = 0.012$; Table 4), with a global reduction of 18% of fasting glycaemia in the FOS group compared to the control group. The greater reduction in fasting blood glucose with FOS intake was observed in rodents fed a high-fat diet (−22%). In parallel, a decrease in fasting insulinaemia was only observed when comparing control and FOS groups fed a low fat diet ($P = 0.014$).

**Quantitative analysis: effect of FOS dose**
A consistent effect with the qualitative model was obtained with the linear model (Table 5). Fasting glycaemia decreased linearly with FOS dose (0 to 13%), whatever the metabolic health and the diet administered throughout the experiment ($−0.17$ mmol/L per 1% FOS supplementation; $P = 0.002$; Table 5). A significant dose effect was also observed for basal insulinaemia ($−6.46$ pmol/L per 1% FOS supplementation; $P = 0.04$), particularly in healthy rodents ($P = 0.002$) and in rodents fed a low-fat diet ($P = 0.016$), with no significant difference in animals fed a high-fat diet ($P = 0.22$), probably due to the small volume of available data (Table 5).

**Other metabolic effects**
In addition to glucose and insulin concentration data, most authors also studied incretin effect and lipid profile after FOS supplementation in rodents (Tables 1 and 2). In most of the studies, FOS supplementation caused an increase in intestinal GLP-1 and proglucagon mRNA content. FOS supplementation also increased fasting and postprandial GLP-1 concentrations, as well as PYY concentration when analysed. FOS supplementation decreased triglyceride concentration in half of the studies. Cholesterol reduction with prebiotic intake was less consistent. Two studies reported a reduction in plasma inflammatory markers with FOS supplementation: LPS in obese mice fed a high-fat diet, and haptoglobin in obese dogs subjected to a weight-loss program (Tables 2 and 3).

**Microbiota modifications**
Some studies also analysed microbiota composition and/or fermentative activity (Table 6). In response to FOS consumption, the weight of caecum (tissue and/or content) was increased, reflecting a higher fermentative activity of the microbiota. When measured, short-chain fatty acid (SCFA) content was increased in the FOS-supplemented group, and particularly propionate and butyrate. Microbiota composition was also modified by FOS supplementation and notably by an increase in Bifidobacterium, Lactobacillus and Clostridium coccoides, and by a reduction in Clostridium leptum. Effects on Bacteroides/Prevotella ratio were more controversial (Table 6).

**Discussion**
The aim of the current paper was to undertake a systematic review and a meta-analysis of animal studies to evaluate the effect of FOS supplementation on glucose homeostasis. Overall, the results from rodent studies showed that regular consumption of FOS significantly reduces fasting glycaemia compared to non-supplemented animals, whatever the metabolic status of the animals and their type of diet. The range of FOS supplementation was 5 to 13% of the total diet and its duration was between 2 to 14 weeks. Interestingly the reduction in fasting glycaemia was more pronounced when rodents were fed a high-fat diet (−22%) compared to a low-fat diet (−10%) and when rodents were obese or diabetic (−17%) compared to healthy (−10%). These results suggest that the effects of FOS supplementation are more pronounced in the event of glucose homeostasis failure in rodents.

Effects of FOS supplementation on fasting insulinaemia were inconsistent. In the meta-analysis, a trend towards lower fasting insulinaemia with FOS supplementation was obtained when unhealthy and healthy rodents were gathered (Table 4); however, this parameter was strongly influenced by the single study made on obese rats in which fasting insulinaemia was reduced by 73% [20]. The effect of FOS supplementation on fasting insulinaemia seemed to be dependent on the type of diet given to the rodents, with a significant effect of FOS supplementation on fasting insulin decrease in rodents fed a standard diet only (less than 20% of energy
provided by fat). However, there were only few data available for a high-energy diet, which may have contributed to the lack of significance of FOS supplementation effect with this type of diet in rodents.

In other animal models than rodents, no effect of FOS on fasting glycaemia has been observed as seen in cats [32], dogs [30, 31], horses [28], and veal calves [33]. On the other hand, fasting insulinaemia decreased in obese horses with FOS supplementation [28], and did not change in other species [32, 33]. Similarly, a recent meta-analysis performed on 26 trials involving 831 humans [34] consuming all types of prebiotics did not show significant difference in fasting glycaemia and reported inconsistent results on fasting insulinaemia. This inconsistency of the results could be due to a lack of standardization of the insulin assay procedure, making it hard to compare absolute plasma insulin concentration values from one laboratory to another [35]. Thus, fasting insulinaemia seems to be a poor parameter for evaluating the effect of FOS supplementation on glucose homeostasis.

### Table 4: Meta-analysis of the FOS supplementation effect on fasting blood glucose and insulin concentrations in rodents

| Parameter                        | Metabolic health or diet     | Treatment | N  | Mean ± SEM | Minimum value | Maximum value | P-value | Treatment |
|----------------------------------|------------------------------|-----------|----|------------|---------------|---------------|---------|-----------|
| Fasting blood glucose, mmol/l    | Healthy + unhealthy          | Control   | 15 | 10.6 ± 1.6 | 4.8           | 25.2          | 0.0124  |           |
|                                  |                              | FOS       | 17 | 8.7 ± 1.3  | 4.6           | 26.3          |         |           |
|                                  | Healthy                      | Control   | 7  | 6.8 ± 0.4  | 4.8           | 8.3           | 0.002   |           |
|                                  |                              | FOS       | 9  | 6.1 ± 0.4  | 4.6           | 8.1           |         |           |
|                                  | Unhealthy (obese or diabetic)| Control   | 8  | 13.9 ± 2.6 | 5.5           | 25.2          | 0.0398  |           |
|                                  |                              | FOS       | 8  | 11.5 ± 2.5 | 4.7           | 26.3          |         |           |
|                                  | Low-fat (< 20%E)             | Control   | 7  | 8.9 ± 2.7  | 4.8           | 25.2          | 0.0083  |           |
|                                  |                              | FOS       | 9  | 8.0 ± 2.3  | 4.6           | 26.3          |         |           |
|                                  | High-fat (> 20%E)            | Control   | 8  | 12.0 ± 1.9 | 5.7           | 18.3          | 0.0225  |           |
|                                  |                              | FOS       | 8  | 9.4 ± 1.3  | 4.7           | 13.4          |         |           |
| Fasting blood insulin, pmol/l    | Healthy + unhealthy          | Control   | 6  | 155.3 ± 29.4 | 73.7         | 253         | 0.0936  |           |
|                                  |                              | FOS       | 8  | 116.1 ± 23.8 | 52.6         | 225         |         |           |
|                                  | Healthy                      | Control   | 5  | 135.8 ± 26.9 | 73.7         | 214.8       | 0.5922  |           |
|                                  |                              | FOS       | 7  | 122.6 ± 26.5 | 52.6         | 225         |         |           |
|                                  | Unhealthy (obese or diabetic)| Control   | 1  | 253.0      | –             | –            |         |           |
|                                  |                              | FOS       | 1  | 70.6       | –             | –            |         |           |
|                                  | Low-fat (< 20%E)             | Control   | 3  | 160.1 ± 50.9 | 77.4         | 253         | 0.0136  |           |
|                                  |                              | FOS       | 5  | 74.4 ± 10.1 | 52.6         | 110         |         |           |
|                                  | High-fat (> 20%E)*            | Control   | 3  | 150.5 ± 41.2 | 73.7         | 214.8       | 0.2159  |           |
|                                  |                              | FOS       | 3  | 185.7 ± 32.8 | 120.5        | 225         |         |           |

*E energy, FOS fructo-oligosaccharides

*Only on healthy animals (not enough data on unhealthy animals)

### Table 5: Meta-analysis of the effect of FOS dose supplementation on rodents fasting blood glycaemia and insulinaemia

| Parameter                        | Metabolic health or diet     | N  | Intercept | Slope  | P-value | Dose SD |
|----------------------------------|------------------------------|----|-----------|--------|---------|---------|
| Fasting blood glucose, mmol/l    | Healthy + unhealthy          | 32 | 9.74      | –0.17  | 0.0022  | 0.32    |
|                                  | Healthy                      | 16 | 6.84      | –0.085 | 0.0007  | 0.012   |
|                                  | Unhealthy (obese or diabetic)| 16 | 12.98     | –0.243 | 0.012   | 0.566   |
|                                  | Low-fat (< 20%E)             | 16 | 8.93      | –0.035 | 0.0035  | 0.012   |
|                                  | High-fat (> 20%E)            | 16 | 10.48     | –0.261 | 0.0054  | 0.526   |
| Fasting blood insulin, pmol/l    | Healthy + unhealthy          | 14 | 154.4     | –6.46  | 0.0386  | 7.02    |
|                                  | Healthy                      | 12 | 134.74    | –0.459 | 0.0022  | 7.67    |
|                                  | Unhealthy (obese or diabetic)| –  | –         | –      | –       | –       |
|                                  | Low-fat (< 20%E)             | 8  | 158.4     | –16.45 | 0.0159  | 9.79    |
|                                  | High-fat (> 20%E)            | 6  | 150.5     | 3.52   | 0.216   | 13.90   |

*E energy, FOS fructo-oligosaccharides
Table 6 Effects of scFOS/OF supplementation on microbiota composition and/or fermentative activity

| Animal model                          | Diet                                      | FOS dose  | Duration | Microbiota fermentative activity                                      | Microbiota composition                                                                 | References |
|---------------------------------------|-------------------------------------------|-----------|----------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|------------|
| Male Wistar rats                      | 11.8% E fat, 69.4% E CHO (starch or fructose) | 10% OF    | 4 w      | ↑ caecum weight                                                        | ND                                                                                       | [61]       |
| C57BL/6J female mice, depleted or not in n-3 PUFA | 14.3% E fat, 58.9% E CHO               | 0.2g OF/ d | 24 d     | ↑ caecal tissue and content weight                                     | ↑ acetate, ↓ propionate and butyrate                                      | [22]       |
| Male C57BL/6J gnotobiotic mice        | 34.9% E fat, 26.3% E CHO                  | 10% scFOS | 6 w      | ↑ empty and full caecum weight                                         | Faeces: ↑ Bifidobacteria, C. coccoides ↓ C. leptum, ratio Bacteroides-Prevotella: C. coccoides | [46]       |
| Male Sprague-Dawley rats, DIO         | 9.8% E fat, 77.5% E CHO                   | 3% OF     | 6 w      | ND                                                                     | Caecum: ↑ Total bacteria ↑ Lactobacillus, Bifidobacterium and Bacteroides-Prevotella, ↓ C. leptum, ratio Bacteroides: Lactobacillus, Bacteroides Xl and I, Enterobacteriaceae ↓ Ratio Firmicutes: Bacteroidetes | [17]       |
| Male Sprague-Dawley rats, DIO         | 9.8% E fat, 77.5% E CHO                   | 10% OF    | 8 w      | ↑ caecum weight                                                        | Caecum: ↑ Bifidobacterium and Lactobacillus, Bifidobacterium spp., B. animalis, ↓ C. coccoides, C. leptum, Clostridium Cluster Xl and I, Enterobacteriaceae, ↓ Ratio Firmicutes: Bacteroidetes | [14]       |
| Male Wistar rats – PX - 407            | 9.8% E fat, 77.5% E CHO                   | 10% or 15% scFOS | 6 w      | ND                                                                     | Caecum: ↑ Bifidobacterium and Lactobacillus, Bifidobacterium spp., B. animalis, ↓ C. coccoides, C. leptum, Clostridium Cluster Xl and I, Enterobacteriaceae, ↓ Ratio Firmicutes: Bacteroidetes | [56]       |
| Male Sprague-Dawley rats, DIO         | 9.8% E fat, 77.5% E CHO                   | 10% OF    | 7 w      | ↑ empty caecum weight                                                 | Faeces: ↑ Total bacteria ↑ Bifidobacterium spp. ↓ C. leptum = Lactobacillus spp., C. coccoides, Bacteroides/Prevotella | [24]       |
| Male Wistar rats, Streptozotocin       | 20.4% E fat, 59.9% E CHO                  | 10% scFOS | 2 – 6 w  | ↑ caecum weight                                                        | Caecum: ↑ Bifidobacteria, Lactobacilli                                      | [19]       |
| Ob/ob C57BL/6 mice                    | 60% E fat, 20% E CHO                      | 10% OF    | 5 w      | ↑ caecum and colon weight                                              | Caecum (qPCR): ↑ Total bacteria ↑ Bifidobacterium spp., E. rectale/ C. coccoides group, ↓ Firmicutes and Roseburia spp. = Bacteroides, Lactobacillus spp., Bacteroides-Prevotella group | [18]       |

CHO carbohydrates, d days, DIO diet-induced obesity, E energy, FOS fructo-oligosaccharides, G glucose, I insulin, ND no data, OF oligofructose, scFOS short-chain fructooligosaccharides, w weeks
Yet, the lowering effect of a FOS supplementation on fasting glycaemia is well demonstrated in rodents, while things are less clear with the other animal models or in humans. Many more studies and data are available in rodent models compared to other animal models and data in humans, as well as the higher dose of supplementation used in rodents, may partly explain why FOS supplementation has demonstrated significant effects in rodents only, the number of studies in other species being too low to underpin any significant effect. In addition, a recent review suggested that postprandial glycaemia was a better predictor of overall glycaemic control than fasting glycaemia [36].

In postprandial conditions such as fed state, or after a glucose homeostasis challenge with a glucose bolus, FOS supplementation reduced glycaemic response in most of the studies selected in our review, though with various effects on insulinaemia. In our bibliography research on rodents, decreased postprandial glucose was concomitantly observed with either an increase [15, 37], no effect [18, 38, 39], or a decrease [14, 40, 41] in postprandial insulinaemia. It is worth mentioning that increased postprandial insulinaemia with FOS supplementation was observed in two studies conducted in diabetic rodents (induced by HF diet or treatment) where glucose-stimulated insulin secretion was significantly reduced [15, 37]. Under these specific conditions, FOS supplementation made it possible to normalize postprandial insulin concentration, bringing it in line with that of non-diabetic rodents. Two studies showed an improvement in insulin sensitivity in obese dogs and horses [28, 30]. The meta-analysis performed in humans indicated a statistically significant effect of FOS supplementation on postprandial glucose and insulin, supporting the fact that prebiotic consumption results in a reduction of both postprandial glucose and insulin concentrations [34]. Altogether, β-fructan improves glucose homeostasis by different mechanisms, depending on metabolic status.

Even though the effects on glycaemia were the same under fasting and postprandial conditions in rodents, the results obtained in dynamic model reflect the adaptability of the organism. Indeed, the dysglycaemia worsening process in type 2 diabetes, for example, is marked first by an early loss of postprandial glycaemic control, preceding a deterioration of fasting glycaemia leading to chronic sustained fasting hyperglycaemia. So, the results obtained in the dynamic model are probably earlier markers of the effect of FOS on glucose metabolism than fasting values. Moreover, it has been recommended to take into account the respective contribution of both fasting and postprandial conditions for assessing glucose homeostasis [42]. However, as dynamic models may be invasive, finding “easy-to-sample” markers is useful for the evaluation of the prebiotic efficiency in practical life.

The gut microbiota has emerged as an integral factor that impacts host metabolism with some evidence for its direct involvement in insulin sensitivity. Also, considering this interplay between gut microbiota and host insulin sensitivity [43], the effects of scFOS/OF on glucose homeostasis presented here probably occurred through microbiota modulations. FOS are prebiotic fibres selectively fermented by the microbiota inhabiting the large intestine [12]. While scFOS and OF may not influence the composition of the microbiota in exactly the same way [44], their fermentation would generally stimulate the growth of some Bifidobacteria and Lactobacilli groups (Table 6), and also directly or indirectly stimulate the growth of lactate-utilizing bacteria [44, 45] and Clostridium coccoides [46]. The fermentation of FOS by the intestinal microbiota is generally complete, leading to an increase in SCFA production [47–53], and more particularly a long-term increase in faecal butyrate, sometimes following a transient increase in lactate production [48]. The mechanisms linking microbiota and glucose homeostasis have been partly elucidated, notably thanks to studies in rodents, and this includes modulation of host signalling through bacterial fermentation products such as SCFA. Indeed, SCFA can bind to the G protein-coupled receptors GPR41 and GPR43, which are widely expressed on intestinal epithelial, enteroenodocrine and immune cells, but also in other metabolically important tissues such as adipose tissues, liver and pancreas [54]. For instance, acetate and propionate, and propionate and butyrate, through GPR43 and GPR41 binding respectively on intestinal enteroenodocrine cells, regulate the secretion of intestinal hormones involved in glucose metabolism regulation. Tolhurst et al. (2012) demonstrated that SCFA, and particularly acetate and propionate, enhanced the release of GLP-1 in an in vitro model of colonic culture. They also showed that mice lacking gpr41 or gpr43 exhibited reduced SCFA-triggered GLP-1 secretion in vivo and developed impaired glucose tolerance, highlighting the important role of SCFA on glucose metabolism through GLP-1 secretion [7]. Interestingly scFOS supplementation (5% for 4 weeks) increased the density of GPR43-positive enteroenodocrine cells in rat proximal colon by over two-fold in comparison to control non-supplemented rats, in parallel to an increased density of GLP-1 containing L-cells [55]. Therefore, GPR43 activation by SCFA might be an important trigger for the production and release of GLP-1. In our literature review, scFOS or OF supplementation reduced post-prandial glucose with, in most studies, a concomitant increase in GLP-1 concentration together with a higher number of enteroenodocrine L-cells, both in healthy and obese or diabetic rodents, whatever the pattern of post-prandial insulinaemia [14, 15, 18, 24, 41, 56–58]. These data are in agreement with a microbiota – host metabolism interplay.
involving GLP-1 release. In addition, SCFA are involved in the regulation of lipid metabolism and adipose tissue [59]. For example, a butyrate supplementation decreased the blood concentration of cholesterol and triglycerides in mice fed HF diet [60], in accordance with the study of Busserolles et al. (2003) included in our systematic review, where an increase in butyrate content in the caecum paralleled a reduction of plasma triglycerides in rats supplemented with OF [61]. Furthermore, a meta-analysis conducted in rodents confirmed the possible benefits of scFOS to reduce visceral fat mass deposition that is a risk factor for metabolic disorders as type-2 diabetes [62]. This suggests inter-relationships between lipid and glucose metabolisms involving microbiota changes. However, the inconsistent results on blood cholesterol and triglycerides in our systematic review require more investigations.

Other signaling pathways mediating crosstalk between gut bacteria and host glucose homeostasis have been identified, through the production of bile acids for instance [63]. Several studies have shown that the gut microbiota impacted bile acid metabolism and signalling by biotransforming bile acids through deconjugation, dehydroxylation, and reconjugation [64]. This may regulate the bile acid pool and composition. Primary bile acids are produced by the liver and recirculated to the liver from the gut. The primary deconjugated/dehydroxylated bile acids are further metabolized by gut bacteria in secondary bile acids [9]. Animal studies and cell culture experiments suggest that bile acids can contribute, via nuclear farnesoid X receptor (FXR) and membrane G-protein-receptor (TGR5), to beneficial effects on glucose metabolism [65–67]. Activation of FXR by bile acid or administration of an FXR agonist lowered fasting plasma glucose and improved insulin sensitivity in obese and diabetic mice [68, 69], whereas FXR-deficient mice showed impaired glucose tolerance and decreased insulin sensitivity [68, 70]. TGR5 are expressed at high levels in the small and large intestines and their activation by bile acid stimulates GLP-1 production in an enteroendocrine cell line [71]. Thomas et al. (2009) further showed that administration of a potent TGR5 agonist INT-777 enhances GLP-1 secretion [67].

FOS supplementation modifies the bile acid profile. ScFOS supplementation in mice induces modifications in microbiota composition (C. coccoides and C. leptum groups), which are correlated to several phenotypic and metabolic parameters, especially to the faecal and blood concentrations of bile acids [46]. Similarly, scFOS intake in humans induces increased concentration of faecal total primary bile acids, associated with higher levels of primary bile acids, but with a decrease in secondary bile acids [72]. Cholesterol may be a blood marker related to biliary acid pattern. However, in our meta-analysis, FOS and OF supplementation did decrease triglyceride concentration in half of the studies whereas results on cholesterol were less consistent. Total cholesterol is not an exhaustive enough parameter to conclude on cholesterol metabolism and informations on LDL- and HDL-cholesterol concentrations would have been necessary to conclude.

The microbiota can also contribute to glucose homeostasis via its impact on inflammatory status. The microbiota is involved in the development of metabolic endotoxemia observed in obese and diabetic individuals or in those consuming a high-fat diet, through the production of inflammatory molecules such as LPS [73]. Microbiota composition modulation after a high-fat diet has been associated with an increased concentration of LPS, in parallel to an alteration of glucose metabolism [74]. In this review, only two studies have analysed the inflammatory profile in parallel to glucose metabolism response. The first one showed a reduction in LPS concentration in ob/ob mice fed a high-fat diet supplemented with prebiotic, associated with changes in microbiota composition [18]. In the second study, scFOS supplementation reduced plasma haptoglobin concentration, a hallmark of inflammation, in obese dogs subjected to a weight loss program [31]. In addition, the team of Cani et al. clearly demonstrated that changes in gut microbiota induced by FOS supplementation decreased inflammatory status in mice with metabolic disorders [75].

To summarize, FOS supplementation improved glucose homeostasis in rodents by mechanisms that could involve their well-known impact on gut microbiota composition towards higher SCFA production, a change in bile acid profile favouring the secretion of GLP-1, and reduced pro-inflammatory compound production. Our bibliography study confirms that dynamic and post-prandial parameters are more efficient for measuring the effects of FOS supplementation, than fasting parameters.

Implication for human
Our understanding of the mechanisms that control glucose metabolism has benefited from the use of rodent models in metabolic research because similarly to humans, their glucose homeostasis is mainly controlled by insulin release in response to blood glucose and the insulin sensitivity of peripheral organs [76]. Although rodents become glucose intolerant in response to diet-induced obesity over time, they are quite resistant to the development of frank diabetes, that is why researchers relied on pharmacological (e.g. streptozotocin) or genetic models (e.g. Zucker fatty rats) of type 2 diabetes [77]. These models enable to study specific components of glucose intolerance and type 2 diabetes. A wide variety of rodent models were included in our meta-analysis suggesting that improvement of glucose homeostasis by
FOS is rather consistent and effective in different conditions. Furthermore, the reduction rates of fasting glycaemia with FOS/OF supplementation observed in rodents would be efficient enough to normalize glycaemia in humans during metabolic disorder development. Indeed, in the case of glucose intolerance, plasma glucose increases by approximately 11% compared to normal glycaemia (> 6.1 mM vs 5.5 mM) and even by 27% in the case of type 2 diabetes mellitus (> 7 mM) [78]. Thus, reducing glycaemia by 10 to 22% with FOS supplementation in the diet as observed in rodents, would be relevant for humans suffering from metabolic disorders to prevent the development of these physiopathological states.

Moreover, rodents may be a good model to study the interplay of gut microbiota changes and development of metabolic diseases in humans, due to their comparable gut physiology and anatomy, and their large extent share of the gut microbiota, not only at the phyla level, but also at the genera level [79–81]. The use of gnotobiotic model is an interesting tool to further increase similarities between animal models and humans and decipher the relationship between gut microbiota and metabolic parameters [46].

It is, however, important to keep in mind that animal models always have some degree of dissimilarity with human physiology. Therefore, results from animal models, including the rodents, are not always directly applicable to humans. Clear differences do exist between species with regard to metabolic regulation [82] and conclusions should be made with caution, especially concerning the conditions under which the effect could be observed in humans, including the daily dose and the minimum duration of dietary supplementation.

Technological advances by using “omics” approaches are enabling scientists to conduct their research in human subjects without using animals in a broad range of disciplines, with non-invasive or minimally invasive techniques. The identification of new biomarkers would allow their common clinical use for diagnosis and monitoring of metabolic disorders.

Conclusion

In conclusion, this review, by using rodent model, evidenced from different short-term trials, that the use of dietary FOS can be considered as a beneficial dietary intervention for the reduction of circulating postprandial glucose and insulin concentration in metabolic physiopathology. Some previous studies in rodents correlated these findings with changes in the growth and function of specific gut bacteria.

Long-term prospective trials investigating primary metabolic end points are now required in humans to be able to make practical recommendations.
12. Roberfroid MB, Gibson GR, Hoyle L, Al MC, Rastall RA, Rowland IR, Wolters D, Watz B, Szejwak H, Stahl B, et al. Prebiotics: effects on metabolic and health benefits. Br J Nutr. 2010;104.
13. Bosusi NKA, Johnson CS, McLeod KM. Can dietary fructans lower serum glucose? J Diabetes. 2011;13:58–66.
14. Bomhof MR, Saha DC, Reid DT, Paul HA, Reimer R. Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycaemia in obese rats. Obesity. 2014;22:763–71.
15. Cani PD, Knauf C, Isgaard M, Drucker DJ, Delzenne NM, Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by Oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes. 2006;55:1484–90.
16. Delmé E, Cani PD, Guá G, Knauf C, Burcelin R, Maton N, Delzenne NM. Relation between colonic proglucagon expression and metabolic response to oligofructose in high-fat-fed mice. Life Sci. 2006;79:1007–13.
17. Eijling AJ, Eier UK, Reimer R. Yellow pea fiber improves glycemia and reduces Clostridium Leptum in diet-induced obese rats. Nutr Res. 2014;34:714–22.
18. Everard A, Lazarevic V, Derrien M, Girard M, Mucuolli GM, Neyrinck AM, Possemiers S, van Holle A, François P, De Vos WM, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic and diet-induced leptin resistant mice. Diabetes. 2011;60:2775–86.
19. Gobinath D, Madhu A, Prashant G, Srinivasan K, Prapulla S. Beneficial effect of xylo-oligosaccharides and fructo-oligosaccharides in streptozotocin-induced diabetic rats. Br J Nutr. 2010;104:440–7.
20. Kaume L, Gilbert W, Gadang V, Devareddy L. Dietary supplementation of fructooligosaccharides reduces hepatic steatosis associated with insulin resistance in obese Zucker rats. Funct Foods Heal Dis. 2011;5:199–213.
21. Kuryl T, Krejczio Z, Wojciak RW, Lipko M, Debiski B, Staniek H. Chromium (III) propionate and dietary fructans supplementation stimulate erythrocyte glucose uptake and beta-oxidation in lymphocytes of rats. Biol Trace Elem Res. 2006;114:357–48.
22. Pachhikam BD, Neyrinck AM, Portois L, De Backer F, Sohet FM, Hacquebard M, Carpentier YA, Cani PD, Delzenne NM. Involvement of gut microbial fermentation in the metabolic alterations occurring in n-3 polyunsaturated fatty acids-depleted mice. Nutrition Metabolism. 2011;8:44.
23. Phuwanmongkolwiwat P, Suzuki T, Hira H, Hara M. Fructooligosaccharide augments benefits of quercetin-3-O-β-glucoside on insulin sensitivity and plasma total cholesterol with promotion of flavonoid absorption in sucrose-fed rats. Eur J Nutr. 2013, ahead of print.
24. Pyra KA, Saha DC, Reimer R. Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats. J Nutr. 2012;142:213–20.
25. Shinoki A, Hara H. Dietary fructooligosaccharides improve insulin sensitivity along with the suppression of adipocytes secretion from mesenteric fat cells in rats. Br J Nutr. 2011;106:1190–7.
26. Desnoyers M, Giger-Reverdin S, Bertin G, De Vaux-Ponter C, Sauvant D. Meta-analysis of the influence of Saccharomyces cerevisiae ceresin on ruminal parameters and milk production or ruminants. J Dairy Sci. 2009;92:1620–32.
27. St-Pierre. Invited review: integrating quantitative findings from multiple studies using mixed mdel methodology. J Dairy Sci. 2001;84(4):741–55.
28. Respondek F, Myers K, Smith TL, Wagner A, Geor RJ. Dietary supplementation with short-chain fructo-oligosaccharides improves insulin sensitivity in obese horses. J Anim Sci. 2011;89:77–83.
29. Kaufhold JN, Hammom HM, Blum JW. Fructo-oligosaccharides supplementation: effects on metabolic, endocrine and hematological traits in veal calves. J Vet Med A. 2000;47:17–29.
30. Respondek F, Svanos SN, Belitsk K, Vester B, Wagner A, Istasse L, Diez M. Short-chain Fructooligosaccharides influence insulin sensitivity and gene expression of fat tissue in obese dogs. J Nutr. 2008;138:1712–8.
31. Ricci R, Jeuseit I, Godau JM, Contiero B, Diez M. Effect of short-chain fructooligosaccharides-enriched energy-restricted diet on weight loss and serum haptoglobin concentration in beige dogs. Br J Nutr. 2011;105:5120–3.
32. Verbrugghe A, Hesta M, Gommeren K, Damitier S, Wuyts B, Biuse Y, Janssens GP. Oligofructose and inulin modulate glucose and amino acid metabolism through propionate production in norma-weight and obese cats. Br J Nutr. 2009;102:694–702.
in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol. 2011;42:27–38.
56. Bharti SK, Krishnan S, Kumar A, Rajak KK, Murari K, Bharti BK, Gupta AK. Antidiabetic activity and molecular docking of fructooligosaccharides produced by Aureobasidium pullulans in poloxamer-407-induced T2DM rats. Food Chem. 2013;136:813–21.
57. Cani PD, Neyrinck AM, Maton N, Delzenne NM. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. Obes Res. 2005;13:1000–7.
58. Hira T, Ikee A, Kishimoto Y, Kanahori S, Hara H. Resistant maltodextrin promotes fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in rats. Br J Nutr. 2015;114:34–42.
59. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200.
60. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitvity and increases energy expenditure in mice. Diabetes. 2009;58:1509–17.
61. Bussellolle J, Gueux E, Rock E, Demign C, Mazur A, Rayssiguier Y. Oligofructose protects against the Hyperglycemic and pro-oxidative effects of a high fructose diet in rats. J Nutr. 2003;133:1903–8.
62. Respondek F, Herpin F, Apper E, Schaller R, Wagner A, Allaert FA. Effects of short-chain fructooligosaccharides on visceral adiposity Meta-analysis in Animal Model. Prague: 34th International Symposium on Diabetes and Nutrition; 2016. p. 45.
63. Uitschneider KM, Kratz M, Dammann CJ, Hullagen M. Mechanisms linking the gut microbiome and glucose metabolism. J Clin Endocrinol Metab. 2016;101:1445–54.
64. Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–59.
65. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diabetes Rep. 2011;11:160–6.
66. Qi Y, Jiang C, Cheng J, Krausz KW, Li T, Ferrell JM, Gonzalez FJ, Chiang JY. Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim Biophys Acta. 2015;1851:19–29.
67. Thomas C, Giotelli A, Noriega L, Strehe A, Oury J, Rizzo G, Macchiariolo A, Yamamoto H, Matak M, Prazanski M, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–77.
68. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102–9.
69. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–11.
70. Carluo B, van Hamelen K, Duran-Sandoval D, van Dijk TH, Greffastro A, Abdelkairim M, Caron S, Torpier G, Fruchart J-C, Gonzalze FJ, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–49.
71. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes. 2012;2:e28.
72. Routron-Rault M, Menteau P, Lavergne-Slove A, Myara A, Gerhardt MF, Franchisseur C, Bomet F. Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small large colorectal adenomas. Nutr Cancer. 2005;53:160–8.
73. Boutilay NE, McMillan RP, Fristad MJ, Hulver MW. Metabolic endotoxemia with obesity: is it real and is it relevant? Biochimie. 2016;124:11–20.
74. Neyrinck AM, Van Herre VF, Piironst N, De Backer F, Toussaint O, Cani PD, Delzenne NM. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satiogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes. 2012;2:e28.
75. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Nolain D, Neyrinck A, Lambert DM, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–103.
76. Rowe JE, Franklin ZJ, Hauge-Evans AC, King AJ, Parsaad SJ, Jones PM. Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol. 2014;222:G13–25.
77. Grayson BE, Seeley RJ, Sandoval DA. Wired on sugar: the role of the CNS in the regulation of glucose homeostasis. Nat Rev Neurosci. 2013;14:24–37.
78. WHO/IDF. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization IDF; 2006.
79. Kych L, Hansen CH, Hansen AK, van den Berg FW, Nielsen DS. Quantitatively different, yet qualitatively alike: a meta-analysis of the mouse core gut microbiome with a view towards the human gut microbiome. PLoS One. 2013;8:e62578.
80. Nguyen TL, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech. 2015;8:1–16.
81. Wos-Oxley M, Bleich A, Oxley AP, Kahl S, Janus LM, Smoczek A, Nahrstedt H, Pils MC, Taudien S, Platen M, et al. Comparative evaluation of establishing a human-gut microbiome community within rodent models. Gut Microbes. 2012;3:234–49.
82. Kowalski GM, Bruce CR. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab. 2014;307:E859–71.
83. Sugatani J, Osabe M, Wada T, Yamakawa K, Yamazaki Y, Takahashi T, Ikari A, Miwa M. Comparison of enzymatically synthesized inulin, resistant maltodextrin and clofibrate effects on biomarkers of metabolic disease in rats fed a high-fat and high-sucrose (cafeteria diet). Eur J Nutr. 2008;47:192–200.
84. Perrin IV, Marchesini M, Rochat FC, Schiffrin EJ, Schitter B. Oligofructose does not affect the development of type 1 diabetes mellitus induced by dietary proteins in the diabetes-prone BB rat model. Diabetes Nutrition. Metabolism. 2003;16:94–101.